Angiocentric  Lymphoma of the Head and Neck:  Patterns of Systemic Failure After Radiation  Treatment

Kim, Gwi Eon; Cho, Jaeho; Yang, Woo Ick; Chung, Eun Ji; Suh, Chang Ok; Park, Kyung Ran; Hong, Won Pyo; Park, In Yong; Hahn, Jae Won; Roh, Jae Kyung; Kim, Byung Soo

doi:10.1200/jco.2000.18.1.54

Cited by 205 publications

(148 citation statements)

References 38 publications

Supporting

Mentioning

138

Contrasting

Unclassified

Order By: Relevance

“…Twenty-seven patients who were treated with RT-2/3DeVIC were evaluated in phase II of the trial. The primary endpoint, the 2-year OS, was 78 % [90 % confidence interval (CI) 61-88 %; 95 % CI 57-89 %], which was superior to the historical control of RT alone (45 %) [17]. Acute toxicity was mild and manageable in patients treated with RT-2/3DeVIC [10].…”

Section: Prospective Clinical Trials For Newly Diagnosed Localized Namentioning

confidence: 89%

“…Prospective clinical trials of concurrent chemoradiotherapy for newly diagnosed localized nasal NKTCL RT alone is insufficient to achieve a high cure rate for patients with localized nasal NKTCL due to frequent infield and systemic relapse [17,20]. To explore a more effective therapy for localized nasal NKTCL, prospective clinical trials of concurrent chemoradiotherapy incorporating chemotherapies with non-MDR-related agents and etoposide, which is effective against EBV-associated hemophagocytic syndrome [35], have been initiated in Japan [10] and soon after in Korea [11].…”

Section: Prospective Clinical Trials For Newly Diagnosed Localized Namentioning

confidence: 99%

“…Thirteen patients were planned to be enrolled according to their statistical considerations. The threshold value of the CR rate was estimated as 70 % of RT alone [17,39], and the expected CR rate was 90 %. The CR rate at the best response was 80 %, which was lower than the expected rate.…”

Section: Prospective Clinical Trials For Newly Diagnosed Localized Namentioning

confidence: 99%

See 2 more Smart Citations

Current and future management of NK/T-cell lymphoma based on clinical trials

Yamaguchi

2012

Int J Hematol

View full text Add to dashboard Cite

Recently reported results of well-designed prospective clinical trials for extranodal NK/T-cell lymphoma, nasal type (ENKL) have rapidly changed the management of ENKL. This review will focus on the evidence obtained from prospective clinical trials for ENKL and discuss the most highly recommended current management and future directions for the better management of ENKL. For patients with nasal NK/T-cell lymphoma of stage IE or contiguous stage IIE with cervical node involvement, concurrent chemoradiotherapy with radiotherapy (RT) and a two-thirds dose of DeVIC chemotherapy is recommended as a first-line treatment. To obtain the expected clinical outcome, performing RT following the same procedure as that reported is important. For the other patients with newly diagnosed ENKL, SMILE chemotherapy is recommended as an induction therapy. The Epstein-Barr virus DNA load in peripheral blood is useful for both prognostication and monitoring during the follow-up after treatment. Other L-asparaginasecontaining chemotherapies and chemotherapies containing non-multidrug resistance-related agents and etoposide are good options for elderly patients or patients with impaired organ function. As in the cases of other aggressive lymphomas, prospective clinical trials with adequate statistical considerations should be conducted to improve the prognosis of patients with ENKL.

show abstract

Section: Prospective Clinical Trials For Newly Diagnosed Localized Namentioning

confidence: 89%

Section: Prospective Clinical Trials For Newly Diagnosed Localized Namentioning

confidence: 99%

See 1 more Smart Citation

Current and future management of NK/T-cell lymphoma based on clinical trials

Yamaguchi

2012

Int J Hematol

View full text Add to dashboard Cite

show abstract

“…3 The prior therapeutic approach with radiotherapy alone for localized disease showed frequent systemic failure, 4,5 which has led to searching for efficient combination modality treatment with chemotherapy and radiotherapy. However, the efficacy of combined modalities of chemotherapy and radiotherapy has been disappointing.…”

Section: Introductionmentioning

confidence: 99%

High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases

Kim

Bang

Lee

et al. 2006

Bone Marrow Transplant

View full text Add to dashboard Cite

“…[4][5][6][7] On the other hand, a favorable role of radiotherapy in the treatment of those lymphomas has been suggested. 2,[8][9][10] In most previously published studies, however, all nasal lymphomas were included irrespective of their phenotype (when available), and NK/T cell lymphomas were not analyzed separately. 2,[8][9][10] In order to further evaluate the role of radiotherapy in localized nasal NK/T cell lymphomas, we performed a retrospective study of patients with nasal NK/T lymphoma treated at our institution over a period of 29 years.…”

Section: Introductionmentioning

confidence: 99%

Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx

et al. 2001

View full text Add to dashboard Cite

Nasal NK/T cell is a rare form of usually localized non-Hodgkin's lymphoma (NHL) which generally carries a poor prognosis when treated with conventional NHL chemotherapy protocols. We reviewed 20 consecutive localized stage I/II nasal NK/T cell lymphomas treated at our institution over a 29 year period. Median age was 44 (range 23-71). Front-line therapy was generally radiotherapy alone (35-70 Gy) before 1980 and combination chemotherapy after 1980. Six patients were treated with first-line radiotherapy and they achieved complete remission (CR). Two subsequently received combination chemotherapy. Five of those patients remained in complete remission, after 97؉ to 277؉ months. Twelve patients were treated with first-line chemotherapy including CHOP or CHOPlike regimen in seven cases, and COP in five cases. Only three of them achieved CR, five had partial response and four had progressive disease. Five of the seven patients treated with CHOP did not achieve complete remission. The nine patients who failed to achieve CR with chemotherapy subsequently received salvage radiotherapy but only two of them obtained CR. Finally, two patients were treated with alternated chemotherapy and radiotherapy and achieved CR, which persisted after 14+ and 26+ months. Median survival was not reached in patients who received front-line radiotherapy, and was 35 months in patients who received front-line chemotherapy. These findings confirm that chemotherapy gives a low complete remission rate in localized nasal NK/T cell lymphoma. By contrast, first-line radiotherapy seems to give favorable results, whereas its results are poorer when administered after resistance to chemotherapy. Whether the use of chemotherapy after radiotherapy, or alternated chemotherapy-radiotherapy regimens give better clinical results than radiotherapy alone will have to be evaluated prospectively in this type of NHL. Leukemia (2001Leukemia ( ) 15, 1123Leukemia ( -1126

show abstract

Angiocentric Lymphoma of the Head and Neck: Patterns of Systemic Failure After Radiation Treatment

Cited by 205 publications

References 38 publications

Current and future management of NK/T-cell lymphoma based on clinical trials

Current and future management of NK/T-cell lymphoma based on clinical trials

High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases

Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx

Contact Info

Product

Resources

About